insights_auto
Outlook: 86.5% bullish·0.0% bearish
Go to analysischevron_right
CSL:ASX
CSL Ltd
A$183.84
arrow_upward
+1.31%(+2.38) 1D
Oct 9, 4:12:42 PM GMT+11 · AUD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CSL...
Open
A$180.80
High
A$184.40
Low
A$180.50
Mkt. cap
88.22B
Avg. vol.
1.16M
Volume
1.04M
Dividend
1.54%
Quarterly dividend
A$0.71
Ex-dividend date
Sep 11, 2023
52-wk high
A$222.47
52-wk low
A$90.00
EPS
-A$7.68
Shares outstanding
479.88M
No. of employees
29K
Open
A$180.80
High
A$184.40
Low
A$180.50
Mkt. cap
88.22B
Avg. vol.
1.16M
Volume
1.04M
Dividend
1.54%
Quarterly dividend
A$0.71
Ex-dividend date
Sep 11, 2023
52-wk high
A$222.47
52-wk low
A$90.00
EPS
-A$7.68
Shares outstanding
479.88M
No. of employees
29K
News stories
From web sources and news partners
AD HOC NEWS
·
1 hour ago
EUR 113.85 at Lang & Schwarz: CSL stock pre-market plus 1.40 percent versus the prior close
StreetInsider
·
14 hours ago
Haemonetics stock surges 17% on CSL Plasma supply deal update
Pluang
·
15 hours ago
Haemonetics shares rise 13% as CSL plans 2027 r...
Yahoo Finance
·
16 hours ago
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
Profile
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994. Wikipedia
About CSL Ltd
CEOPaul McKenzie
Employees29K
Founded1916
HeadquartersMelbourne, Victoria, Australia
SectorBiotechnology
Websitecsl.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 4.17B | 4.17B | 3.73B | 3.73B |
Cost of goods sold | 1.94B | 1.94B | 1.93B | 1.93B |
Cost of revenue | 1.94B | 1.94B | 1.93B | 1.93B |
Research and development expenses | 300.00M | 300.00M | 311.50M | 311.50M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 612.50M | 612.50M | 693.00M | 693.00M |
Operating expense | 912.50M | 912.50M | 1.00B | 1.00B |
Total operating expenses | 2.85B | 2.85B | 2.93B | 2.93B |
Operating income | 1.32B | 1.32B | 802.00M | 802.00M |
Other non operating income | - | - | - | - |
EBT including unusual items | 190.00M | 190.00M | -2.23B | -2.23B |
EBT excluding unusual items | 1.22B | 1.22B | 699.50M | 699.50M |
Income tax expense | 47.00M | 47.00M | -597.50M | -597.50M |
Effective tax rate | 24.74% | 24.74% | 26.75% | 26.75% |
Other operating expenses | - | - | - | - |
Net income | 200.50M | 200.50M | -1.49B | -1.49B |
Net profit margin | 4.81% | 4.81% | -39.92% | -39.92% |
Earnings per share | - | - | - | - |
Interest and investment income | 9.00M | 9.00M | 6.00M | 6.00M |
Interest expense | -106.50M | -106.50M | -108.50M | -108.50M |
Net interest expenses | -97.50M | -97.50M | -102.50M | -102.50M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 1.56B | 1.56B | 974.00M | 974.00M |
Gain or loss from assets sale | 22.50M | 22.50M | 500.00K | 500.00K |